Reducing GABA A α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Down syndrome (DS) is associated with neurological complications, including cognitive deficits that lead to impairment in intellectual functioning. Increased GABA-mediated inhibition has been proposed as a mechanism underlying deficient cognition in the Ts65Dn (TS) mouse model of DS. We show that chronic treatment of these mice with RO4938581 (3-bromo-10-(difluoromethyl)-9H-benzo[f]imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]diazepine), a selective GABA A α5 negative allosteric modulator (NAM), rescued their deficits in spatial learning and memory, hippocampal synaptic plasticity, and adult neurogenesis. We also show that RO4938581 normalized the high density of GABAergic synapse markers in the molecular layer of the hippocampus of TS mice. In addition, RO4938581 treatment suppressed the hyperactivity observed in TS mice without inducing anxiety or altering their motor abilities. These data demonstrate that reducing GABAergic inhibition with RO4938581 can reverse functional and neuromorphological deficits of TS mice by facilitating brain plasticity and support the potential therapeutic use of selective GABA A α5 NAMs to treat cognitive dysfunction in DS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340 · cited 1×
“To test whether RO4938581, through inhibition of the GABAA 5 receptor activity, could improve cognition in TS mice, we used a modified version of the Morris water maze task (Morris et al., 1982) as illustrated in Figure 1a.”
MethodFritschy, J., & Mohler, H. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903590111 · Cited by 1,244
A mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 2×
“This murine model shows several fundamental features of DS, including learning and memory deficits (Escorihuela et al., 1995; Reeves et al., 1995; Holtzman et al., 1996) with alterations in both hippocampal morphology (Insausti et al., 1998; Kurt et al., 2004) and adult neurogenesis (Rueda et al.,…”
BackgroundBeyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733 · cited 1×
“Among the different GABAA receptor subtypes, GABAA 5 subunit-containing receptors are preferentially localized in the hippocampus and play a key modulatory role in cognition (Collinson et al., 2002; Crestani et al., 2002; Rudolph and Knoflach, 2011).”
BackgroundSelf-citationCollinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 1×
“Among the different GABAA receptor subtypes, GABAA 5 subunit-containing receptors are preferentially localized in the hippocampus and play a key modulatory role in cognition (Collinson et al., 2002; Crestani et al., 2002; Rudolph and Knoflach, 2011).”
BackgroundKleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C., & Mobley, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-04.2004 · Cited by 459
Which GABA A Receptor Subunits Are Necessary for Tonic Inhibition in the Hippocampus?
Glykys, J., Mann, E. O., & Mody, I. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4751-07.2008 · Cited by 370 · cited 2×
“GABAA 5 receptors, predominantly localized extrasynaptically, mediate tonic inhibition (Glykys et al., 2008) and regulate the excitability of hippocampal pyramidal neurons by influencing the strength of depolarization required to generate an action potential (Bonin et al.”
BackgroundSynaptic structural abnormalities in the Ts65Dn mouse model of down syndrome
Belichenko, P. V., Masliah, E., Kleschevnikov, A. M., Villar, A. J., Epstein, C. J., Salehi, A., & Mobley, W. C. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20337 · Cited by 297
Kahlem, P., Sultan, M., Herwig, R., Steinfath, M., Balzereit, D., Eppens, B., Saran, N. G., Pletcher, M. T., South, S. T., Stetten, G., et al. (2004) · Genome Research · doi:10.1101/gr.1951304 · Cited by 249
Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome
Siarey, R. J., Stoll, J., Rapoport, S. I., & Galdzicki, Z. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00157-3 · Cited by 222 · cited 2×
“…enhanced GABA-mediated inhibition was associated with deficient synaptic plasticity in the hippocampus of TS mice through a marked reduction in long-term potentiation (LTP) in the CA1 and DG areas (Siarey et al., 1997; Kleschevnikov et al., 2004; Costa and Grybko, 2005; Fernandez et al., 2007).”
Background
Cited by
Rudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Down syndrome and the complexity of genome dosage imbalance
Antonarakis, S. E. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.154 · Cited by 299
Deidda, G., Bozarth, I. F., & Cancedda, L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00119 · Cited by 192
Human Models Are Needed for Studying Human Neurodevelopmental Disorders
Zhao, X., & Bhattacharyya, A. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.10.009 · Cited by 192
Hibaoui, Y., Grad, I., Letourneau, A., Sailani, M. R., Dahoun, S., Santoni, F. A., Gimelli, S., Guipponi, M., Pelte, M. F., Béna, F., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302848 · Cited by 170
Metadata
- Authors
- Martínez-Cué, C., Martínez, P., Rueda, N., Vidal, R., García, S., Vidal, V., Corrales, A., Montero, J. A., Pazos, Á., Flórez, J., Gasser, R., Thomas, A. W., Honer, M., Knoflach, F., Trejo, J. L., Wettstein, J. G., & Hernández, M.-C.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2013-02-27
- Volume
- 33
- Issue
- 9
- Pages
- 3953-3966
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1977391603
- Cited by
- 157
- References
- 19
- FWCI
- 17.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reducing GABA A α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome. https://app.cochat.ai/papers/10.1523/jneurosci.1203-12.2013
- The paper
- Martínez-Cué, C., Martínez, P., Rueda, N., Vidal, R., García, S., Vidal, V., Corrales, A., Montero, J. A., Pazos, Á., Flórez, J., Gasser, R., Thomas, A. W., Honer, M., Knoflach, F., Trejo, J. L., Wettstein, J. G., & Hernández, M.-C. (2013). Reducing GABA A α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.1203-12.2013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.